Pub Date : 2022-08-03eCollection Date: 2022-01-12DOI: 10.4081/mrm.2022.868
Peter Kardos, Walter Lehmacher, Andrea Zimmermann, Juliette Brandes-Schramm, Petra Funk, Heinrich Matthys, Wolfgang Kamin
Background: Cough is a leading symptom of viral acute respiratory infections such as acute bronchitis (AB) and the common cold (CC), which can be debilitating and may persist for several weeks. We investigated whether treatment with Pelargonium extract EPs 7630 may reduce cough and improve disease-related quality of life (QoL).
Methods: We performed a meta-analysis of randomized, placebo-controlled trials investigating the efficacy of EPs 7630 in AB or CC. Efficacy analyses included change from baseline in a cough intensity score, remission of cough, and disease-associated impairments of QoL.
Results: Data of 2,195 participants from 11 trials (3 in children/adolescents with AB, 3 in adults with AB, 5 in adults with CC) were eligible. In children/adolescents with AB, 79.6% of participants treated with EPs 7630 and 41% treated with placebo showed a reduction in the intensity of cough by at least 50% of baseline values at day 7 [meta-analysis rate/risk ratio (RR), EPs 7630 / placebo: 1.86 (95% CI: 1.34; 2.95)], and 18.0% vs 5.5% presented with complete remission of cough [RR: 2.91 (95% CI: 1.26; 6.72)]. In adults with AB, 88.7% of participants in the EPs 7630 group and 47.6% in the placebo group showed a ≥50% response for cough intensity [RR: 2.13 (95% CI: 1.37; 3.31)], while 26.0% vs 6.3% did not cough any more at day 7 [RR: 5.00 [95% CI: 3.10; 8.07)]. Cough scale results were supported by significant improvements over placebo in the pursuit of normal daily activities and other QoL measures. In CC, 56.8% of participants treated with EPs 7630 and 38.8% treated with placebo showed a ≥50% cough intensity reduction [RR: 1.40 (95% CI: 1.19; 1.65)] at day 5, while 26.1% versus 18.4% showed complete remission of cough for EPs 7630 and placebo, respectively [RR: 1.40 (95% CI: 1.06; 1.84)]. CCassociated pain/discomfort and impairment of usual activities were no longer present in 41.5% and 48.8% of participants treated with EPs 7630 compared to less than 40% of patients in the placebo group.
Conclusions: The results show that EPs 7630 reduces the burden and leads to earlier remission of cough. Advantages for EPs 7630 were also reflected in self-rated measures of disease-associated QoL. Of note, patients treated with the herbal product felt able to resume their usual daily activities sooner.
{"title":"Effects of Pelargonium sidoides extract EPs 7630 on acute cough and quality of life - a meta-analysis of randomized, placebo-controlled trials.","authors":"Peter Kardos, Walter Lehmacher, Andrea Zimmermann, Juliette Brandes-Schramm, Petra Funk, Heinrich Matthys, Wolfgang Kamin","doi":"10.4081/mrm.2022.868","DOIUrl":"https://doi.org/10.4081/mrm.2022.868","url":null,"abstract":"<p><strong>Background: </strong>Cough is a leading symptom of viral acute respiratory infections such as acute bronchitis (AB) and the common cold (CC), which can be debilitating and may persist for several weeks. We investigated whether treatment with <i>Pelargonium</i> extract EPs 7630 may reduce cough and improve disease-related quality of life (QoL).</p><p><strong>Methods: </strong>We performed a meta-analysis of randomized, placebo-controlled trials investigating the efficacy of EPs 7630 in AB or CC. Efficacy analyses included change from baseline in a cough intensity score, remission of cough, and disease-associated impairments of QoL.</p><p><strong>Results: </strong>Data of 2,195 participants from 11 trials (3 in children/adolescents with AB, 3 in adults with AB, 5 in adults with CC) were eligible. In children/adolescents with AB, 79.6% of participants treated with EPs 7630 and 41% treated with placebo showed a reduction in the intensity of cough by at least 50% of baseline values at day 7 [meta-analysis rate/risk ratio (RR), EPs 7630 / placebo: 1.86 (95% CI: 1.34; 2.95)], and 18.0% <i>vs</i> 5.5% presented with complete remission of cough [RR: 2.91 (95% CI: 1.26; 6.72)]. In adults with AB, 88.7% of participants in the EPs 7630 group and 47.6% in the placebo group showed a ≥50% response for cough intensity [RR: 2.13 (95% CI: 1.37; 3.31)], while 26.0% <i>vs</i> 6.3% did not cough any more at day 7 [RR: 5.00 [95% CI: 3.10; 8.07)]. Cough scale results were supported by significant improvements over placebo in the pursuit of normal daily activities and other QoL measures. In CC, 56.8% of participants treated with EPs 7630 and 38.8% treated with placebo showed a ≥50% cough intensity reduction [RR: 1.40 (95% CI: 1.19; 1.65)] at day 5, while 26.1% <i>versus</i> 18.4% showed complete remission of cough for EPs 7630 and placebo, respectively [RR: 1.40 (95% CI: 1.06; 1.84)]. CCassociated pain/discomfort and impairment of usual activities were no longer present in 41.5% and 48.8% of participants treated with EPs 7630 compared to less than 40% of patients in the placebo group.</p><p><strong>Conclusions: </strong>The results show that EPs 7630 reduces the burden and leads to earlier remission of cough. Advantages for EPs 7630 were also reflected in self-rated measures of disease-associated QoL. Of note, patients treated with the herbal product felt able to resume their usual daily activities sooner.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":"868"},"PeriodicalIF":2.3,"publicationDate":"2022-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/b5/mrm-17-1-868.PMC9425964.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40344002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-28eCollection Date: 2022-01-12DOI: 10.4081/mrm.2022.871
Filippo Sanfilippo, Claudia Crimi, Alberto Morgana, Luigi La Via, Marinella Astuto
To assess the presence of journal policies discouraging inappropriate author's self-citation (A-SC) in "Respiratory System" journals, we evaluated submission guidelines of "Respiratory System" journals included in Journal-Citation Reports 2020 (Clarivate Analytics®) for the presence of policies on A-SC and its impact on journals' self-citation (J-SC) rate and impact factor (IF). We found that 14.3% of journals (n=8/56) reported policies on inappropriate A-SC. The median IF was not different in "Respiratory System" journals with (3.6; IQR:2.3) vs without A-SC policies (3.1; IQR:3.0; p=0.41). The J-SC rate was not influenced by the presence of A-SC policies (p=0.83). Fully open-access (n=14) and traditional (n=42) journals had no differences in IF (3.3; IQR:1.5 vs 3.1; IQR:3.4, respectively; p=0.77) and J-SC rate (4.5%; IQR:5.6 vs 6.2%; IQR:8.4, respectively; p=0.38). The majority of "Respiratory System" journals do not have policies discouraging A-SC. The presence of such policies is not associated with changes in IF or J-SC rates.
为了评估是否存在阻止“呼吸系统”期刊中不适当作者自引(A-SC)的期刊政策,我们评估了《journal -citation Reports 2020》(Clarivate Analytics®)中包含的“呼吸系统”期刊的投稿指南,以了解A-SC政策的存在及其对期刊自引(J-SC)率和影响因子(IF)的影响。我们发现14.3%的期刊(n=8/56)报告了不适当的A-SC政策。“呼吸系统”期刊的中位数IF无差异,分别为(3.6;IQR:2.3) vs无A-SC政策(3.1;差:3.0;p = 0.41)。J-SC率不受A-SC政策存在的影响(p=0.83)。完全开放获取期刊(n=14)和传统期刊(n=42)在影响因子方面没有差异(3.3;IQR:1.5 vs 3.1;分别差:3.4;p=0.77)和J-SC率(4.5%;IQR:5.6 vs 6.2%;分别差:8.4;p = 0.38)。大多数“呼吸系统”期刊并没有禁止A-SC的政策。这些政策的存在与IF或J-SC利率的变化无关。
{"title":"The influence of policies limiting author self-citations on journals impact factor and self-citation rate in respiratory system.","authors":"Filippo Sanfilippo, Claudia Crimi, Alberto Morgana, Luigi La Via, Marinella Astuto","doi":"10.4081/mrm.2022.871","DOIUrl":"https://doi.org/10.4081/mrm.2022.871","url":null,"abstract":"<p><p>To assess the presence of journal policies discouraging inappropriate author's self-citation (A-SC) in \"Respiratory System\" journals, we evaluated submission guidelines of \"Respiratory System\" journals included in Journal-Citation Reports 2020 (Clarivate Analytics<sup>®</sup>) for the presence of policies on A-SC and its impact on journals' self-citation (J-SC) rate and impact factor (IF). We found that 14.3% of journals (n=8/56) reported policies on inappropriate A-SC. The median IF was not different in \"Respiratory System\" journals with (3.6; IQR:2.3) <i>vs</i> without A-SC policies (3.1; IQR:3.0; p=0.41). The J-SC rate was not influenced by the presence of A-SC policies (p=0.83). Fully open-access (n=14) and traditional (n=42) journals had no differences in IF (3.3; IQR:1.5 <i>vs</i> 3.1; IQR:3.4, respectively; p=0.77) and J-SC rate (4.5%; IQR:5.6 <i>vs</i> 6.2%; IQR:8.4, respectively; p=0.38). The majority of \"Respiratory System\" journals do not have policies discouraging A-SC. The presence of such policies is not associated with changes in IF or J-SC rates.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":"871"},"PeriodicalIF":2.3,"publicationDate":"2022-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/2b/mrm-17-1-871.PMC9425953.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40344003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-06eCollection Date: 2022-01-12DOI: 10.4081/mrm.2022.832
Leticia Burton, Daminda P Weerasinghe, David Joffe, Jennifer Saunders, Gregory L Falk, Hans Van der Wall
Background: Pertussis is an infectious disease of the respiratory tract with a changing epidemiology. An increasing incidence has been found in the adult population with recurrent infections possibly related to changes in the current vaccine. Is there an association between pertussis infection, refractory cough and atypical gastro-oesophageal reflux (GORD)? Does this magnify and compound respiratory complications?
Methods: Observational study which compares post-pertussis (n=103) with non-pertussis patients (n=105) with established GORD. Patients were assessed for laryngopharyngeal reflux and aspiration of refluxate by a novel scintigraphic study.
Results: Both groups showed severe GORD in association with high rates of laryngopharyngeal reflux (LPR) and pulmonary aspiration and lung disease. High rates of hiatus hernia and clinical diagnosis of "atypical" asthma showed correlations with pulmonary aspiration.
Conclusions: A high level of new onset LPR and lung aspiration has been shown in patients with chronic cough after recent pertussis infection by a novel scintigraphic technique with fused hybrid x-ray computed tomography (SPECT/CT).
{"title":"A putative link between pertussis and new onset of gastroesophageal reflux an observational study.","authors":"Leticia Burton, Daminda P Weerasinghe, David Joffe, Jennifer Saunders, Gregory L Falk, Hans Van der Wall","doi":"10.4081/mrm.2022.832","DOIUrl":"https://doi.org/10.4081/mrm.2022.832","url":null,"abstract":"<p><strong>Background: </strong>Pertussis is an infectious disease of the respiratory tract with a changing epidemiology. An increasing incidence has been found in the adult population with recurrent infections possibly related to changes in the current vaccine. Is there an association between pertussis infection, refractory cough and atypical gastro-oesophageal reflux (GORD)? Does this magnify and compound respiratory complications?</p><p><strong>Methods: </strong>Observational study which compares post-pertussis (n=103) with non-pertussis patients (n=105) with established GORD. Patients were assessed for laryngopharyngeal reflux and aspiration of refluxate by a novel scintigraphic study.</p><p><strong>Results: </strong>Both groups showed severe GORD in association with high rates of laryngopharyngeal reflux (LPR) and pulmonary aspiration and lung disease. High rates of hiatus hernia and clinical diagnosis of \"atypical\" asthma showed correlations with pulmonary aspiration.</p><p><strong>Conclusions: </strong>A high level of new onset LPR and lung aspiration has been shown in patients with chronic cough after recent pertussis infection by a novel scintigraphic technique with fused hybrid x-ray computed tomography (SPECT/CT).</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":"832"},"PeriodicalIF":2.3,"publicationDate":"2022-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/94/mrm-17-1-832.PMC9295390.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40528864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-22eCollection Date: 2022-01-12DOI: 10.4081/mrm.2022.843
Adrian A Jarquin-Valdivia, Earl B Glasgow, Todd J Meyer
Introduction: Respiratory therapists (RTs) in the intensive care unit can at times find themselves involved in and assisting during the performance of the apnea test (ApT). The ApT is a clinically complex procedure and is the last part of the clinical declaration of death by neurologic criteria (DNC) protocol and requires close collaboration between the physicians and the RTs. As such, the ApT should be performed with the upmost attention to detail.
Context and aims: The RTs need to be versed on the intricacies of the ApT. Except in very large medical centers, the ApT is not a procedure performed with high enough frequency as to maintain high level of proficiency. For a successful ApT, structured knowledge and preparation are paramount. This publication attempts to fill that gap, for adult hospitalized patients not on ECMO (extracorporeal membrane oxygenation). To generate this report, we make use of the published guidelines, and our personal experience on performing ApTs in large medical centers.
Conclusion: We provide a structure by means of a checklist, from the RTs' perspective, to guide and help them lead on the efficient performance of the ApT.
{"title":"The practical role of the respiratory therapist in the standard apnea test procedure for declaration of death via neurologic criteria in adults.","authors":"Adrian A Jarquin-Valdivia, Earl B Glasgow, Todd J Meyer","doi":"10.4081/mrm.2022.843","DOIUrl":"https://doi.org/10.4081/mrm.2022.843","url":null,"abstract":"<p><strong>Introduction: </strong>Respiratory therapists (RTs) in the intensive care unit can at times find themselves involved in and assisting during the performance of the apnea test (ApT). The ApT is a clinically complex procedure and is the last part of the clinical declaration of death by neurologic criteria (DNC) protocol and requires close collaboration between the physicians and the RTs. As such, the ApT should be performed with the upmost attention to detail.</p><p><strong>Context and aims: </strong>The RTs need to be versed on the intricacies of the ApT. Except in very large medical centers, the ApT is not a procedure performed with high enough frequency as to maintain high level of proficiency. For a successful ApT, structured knowledge and preparation are paramount. This publication attempts to fill that gap, for adult hospitalized patients not on ECMO (extracorporeal membrane oxygenation). To generate this report, we make use of the published guidelines, and our personal experience on performing ApTs in large medical centers.</p><p><strong>Conclusion: </strong>We provide a structure by means of a checklist, from the RTs' perspective, to guide and help them lead on the efficient performance of the ApT.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":"843"},"PeriodicalIF":2.3,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/11/mrm-17-1-843.PMC9261955.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40489456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-01eCollection Date: 2022-01-12DOI: 10.4081/mrm.2022.842
Ahmed E Kabil, Eman Sobh, Mahmoud Elsaeed, Houssam Eldin Hassanin, Ibrahim H Yousef, Heba H Eltrawy, Ahmed M Ewis, Ahmed Aboseif, AbdAllah M Albalsha, Sawsan Elsawy, Abdul Rahman H Ali
Background: Measurement of diaphragmatic motion by ultrasound is being utilized in different aspects of clinical practice. Defining reference values of the diaphragmatic excursion is important to identify those with diaphragmatic motion abnormalities. This study aimed to define the normal range of diaphragmatic motion (reference values) by Mmode ultrasound for the normal population.
Methods: Healthy volunteers were included in this study. Those with comorbidities, skeletal deformity, acute or chronic respiratory illness were excluded. Diaphragmatic ultrasound in the supine position was performed using a lowfrequency probe. The B-mode was applied for diaphragmatic identification, and the M-mode was employed for the recording of the amplitude of diaphragm contraction during quiet breathing, deep breathing and sniffing.
Results: The study included 757 healthy subjects [478 men (63.14%) and 279 women (36.86%)] with normal spirometry and negative history of previous or current respiratory illness. Their mean age and BMI were 45.17 ±14.84 years and 29.36±19.68 (kg/m2). The mean right hemidiaphragmatic excursion was 2.32±0.54, 5.54±1.26 and 2.90±0.63 for quiet breathing, deep breathing and sniffing, respectively, while the left hemidiaphragmatic excursion was 2.35±0.54, 5.30±1.21 and 2.97±0.56 cm for quiet breathing, deep breathing and sniffing, respectively. There was a statistically significant difference between right and left diaphragmatic excursion among all studied subjects. The ratio of right to left diaphragmatic excursion during quiet breathing was (1.009±0.19); maximum 181% and minimum 28%. Only 19 cases showed a right to left ratio of less than 50% (5 men and 14 women). The diaphragmatic excursion was higher in males than females. There was a significant difference in diaphragmatic excursion among age groups. Age, sex and BMI significantly affected the diaphragmatic motion.
Conclusions: Diaphragmatic excursion values presented in this study can be used as reference values to detect diaphragmatic dysfunction in clinical practice. Diaphragmatic motion is affected by several factors including age, sex and body mass index.
{"title":"Diaphragmatic excursion by ultrasound: reference values for the normal population; a cross-sectional study in Egypt.","authors":"Ahmed E Kabil, Eman Sobh, Mahmoud Elsaeed, Houssam Eldin Hassanin, Ibrahim H Yousef, Heba H Eltrawy, Ahmed M Ewis, Ahmed Aboseif, AbdAllah M Albalsha, Sawsan Elsawy, Abdul Rahman H Ali","doi":"10.4081/mrm.2022.842","DOIUrl":"https://doi.org/10.4081/mrm.2022.842","url":null,"abstract":"<p><strong>Background: </strong>Measurement of diaphragmatic motion by ultrasound is being utilized in different aspects of clinical practice. Defining reference values of the diaphragmatic excursion is important to identify those with diaphragmatic motion abnormalities. This study aimed to define the normal range of diaphragmatic motion (reference values) by Mmode ultrasound for the normal population.</p><p><strong>Methods: </strong>Healthy volunteers were included in this study. Those with comorbidities, skeletal deformity, acute or chronic respiratory illness were excluded. Diaphragmatic ultrasound in the supine position was performed using a lowfrequency probe. The B-mode was applied for diaphragmatic identification, and the M-mode was employed for the recording of the amplitude of diaphragm contraction during quiet breathing, deep breathing and sniffing.</p><p><strong>Results: </strong>The study included 757 healthy subjects [478 men (63.14%) and 279 women (36.86%)] with normal spirometry and negative history of previous or current respiratory illness. Their mean age and BMI were 45.17 ±14.84 years and 29.36±19.68 (kg/m<sup>2</sup>). The mean right hemidiaphragmatic excursion was 2.32±0.54, 5.54±1.26 and 2.90±0.63 for quiet breathing, deep breathing and sniffing, respectively, while the left hemidiaphragmatic excursion was 2.35±0.54, 5.30±1.21 and 2.97±0.56 cm for quiet breathing, deep breathing and sniffing, respectively. There was a statistically significant difference between right and left diaphragmatic excursion among all studied subjects. The ratio of right to left diaphragmatic excursion during quiet breathing was (1.009±0.19); maximum 181% and minimum 28%. Only 19 cases showed a right to left ratio of less than 50% (5 men and 14 women). The diaphragmatic excursion was higher in males than females. There was a significant difference in diaphragmatic excursion among age groups. Age, sex and BMI significantly affected the diaphragmatic motion.</p><p><strong>Conclusions: </strong>Diaphragmatic excursion values presented in this study can be used as reference values to detect diaphragmatic dysfunction in clinical practice. Diaphragmatic motion is affected by several factors including age, sex and body mass index.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":" ","pages":"842"},"PeriodicalIF":2.3,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/6a/mrm-17-1-842.PMC9220962.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40400383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-24eCollection Date: 2021-01-15DOI: 10.4081/mrm.2021.779
Francesco Menzella, Carla Galeone, Giulia Ghidoni, Patrizia Ruggiero, Silvia Capobelli, Anna Simonazzi, Chiara Catellani, Chiara Scelfo, Francesco Livrieri, Nicola Facciolongo
Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by necrotizing eosinophilic granulomatous inflammation that frequently involves the respiratory tract (90% of cases). Asthma in EGPA is systematically severe and often refractory to common treatment, it is corticosteroid resistant and can often anticipate the onset of systemic vasculitis by many years. A release of cytokines necessary for the activation, maturation and survival of eosinophils, such as IL-4, IL-5 and IL-13 occurs in the activated Th-2 phenotype. In particular, IL-5 level is high in active EGPA and its inhibition has become a key therapeutic target. Oral glucocorticoids (OCS) are effective treatment options but unfortunately, frequent relapses occur in many patients and they lead to frequent side effects. As for now, there are currently no official recommendations on doses and treatment schedules in the management of EGPA.
Case presentation: In this article, we describe the case of a man with EGPA, severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with poor asthma and CRSwNP control despite OCS and mepolizumab treatment. Respiratory and vasculitis symptoms improved markedly after therapeutic switch to benralizumab. During the treatment, in addition to clinical effects, we witnessed a depletion of blood eosinophils, as well as an improvement in both pulmonary function tests, CT scan and skin lesions present initially.
Conclusions: While there are many studies confirming the efficacy of benralizumab in EGPA, the most interesting aspect of our report is that efficacy was confirmed in a patient previously unresponsive to mepolizumab, known to be effective in EGPA.
{"title":"Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.","authors":"Francesco Menzella, Carla Galeone, Giulia Ghidoni, Patrizia Ruggiero, Silvia Capobelli, Anna Simonazzi, Chiara Catellani, Chiara Scelfo, Francesco Livrieri, Nicola Facciolongo","doi":"10.4081/mrm.2021.779","DOIUrl":"https://doi.org/10.4081/mrm.2021.779","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by necrotizing eosinophilic granulomatous inflammation that frequently involves the respiratory tract (90% of cases). Asthma in EGPA is systematically severe and often refractory to common treatment, it is corticosteroid resistant and can often anticipate the onset of systemic vasculitis by many years. A release of cytokines necessary for the activation, maturation and survival of eosinophils, such as IL-4, IL-5 and IL-13 occurs in the activated Th-2 phenotype. In particular, IL-5 level is high in active EGPA and its inhibition has become a key therapeutic target. Oral glucocorticoids (OCS) are effective treatment options but unfortunately, frequent relapses occur in many patients and they lead to frequent side effects. As for now, there are currently no official recommendations on doses and treatment schedules in the management of EGPA.</p><p><strong>Case presentation: </strong>In this article, we describe the case of a man with EGPA, severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with poor asthma and CRSwNP control despite OCS and mepolizumab treatment. Respiratory and vasculitis symptoms improved markedly after therapeutic switch to benralizumab. During the treatment, in addition to clinical effects, we witnessed a depletion of blood eosinophils, as well as an improvement in both pulmonary function tests, CT scan and skin lesions present initially.</p><p><strong>Conclusions: </strong>While there are many studies confirming the efficacy of benralizumab in EGPA, the most interesting aspect of our report is that efficacy was confirmed in a patient previously unresponsive to mepolizumab, known to be effective in EGPA.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"16 1","pages":"779"},"PeriodicalIF":2.3,"publicationDate":"2021-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/77/mrm-16-1-779.PMC8239622.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39150697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-10eCollection Date: 2021-01-15DOI: 10.4081/mrm.2021.758
Asmaa M Zahran, Zeinab Albadry M Zahran, Yasmeen H Mady, Essam Eldeen M O Mahran, Alaa Rashad, Ahmed Makboul, Khalid A Nasif, Aida A Abdelmaksoud, Omnia El-Badawy
Background: Viral infections cause alteration in the total number of lymphocytes and their subset distribution. We aimed to study peripheral blood lymphocyte subsets in COVID-19 patients and to correlate these subsets with clinical and laboratory data, which may help in clarifying the pathogenesis to develop novel diagnostic and prognostic biomarkers for COVID-19.
Methods: Twenty-six reverse-transcription polymerase chain reaction (RT-PCR) confirmed COVID-19 patients were subjected to medical history-taking and a thorough clinical examination. Laboratory tests included complete blood count, D dimer, ferritin, and C-reactive protein (CRP). Chest CT was used to diagnose COVID-19 pneumonia. Lymphocyte subsets were compared with those in 20 healthy controls using flow cytometry.
Results: Leucopenia, relative neutrophilia, lymphopenia, eosinopenia together with marked elevation in neutrophil/lymphocyte ratio were observed in our COVID-19 patients. A marked reduction was observed in T cells, including both CD4 and CD8 cells, natural killer (NK), and natural killer T cells (NKT). Double-positive T (DPT) cells, double-negative T (DNT) cells, and B cells were elevated in the patients relative to the other lymphocyte subsets.
Conclusion: Immune-inflammatory parameters are of utmost importance in understanding the pathogenesis and in the provisional diagnosis of COVID-19. Yet, adequate care must be taken during their interpretation because of the vast discrepancies observed between studies even in the same locality. Further studies are needed to clarify the role of B cells, DPT, and DNT cells in the pathogenesis and control of COVID-19.
{"title":"Differential alterations in peripheral lymphocyte subsets in COVID-19 patients: upregulation of double-positive and double-negative T cells.","authors":"Asmaa M Zahran, Zeinab Albadry M Zahran, Yasmeen H Mady, Essam Eldeen M O Mahran, Alaa Rashad, Ahmed Makboul, Khalid A Nasif, Aida A Abdelmaksoud, Omnia El-Badawy","doi":"10.4081/mrm.2021.758","DOIUrl":"https://doi.org/10.4081/mrm.2021.758","url":null,"abstract":"<p><strong>Background: </strong>Viral infections cause alteration in the total number of lymphocytes and their subset distribution. We aimed to study peripheral blood lymphocyte subsets in COVID-19 patients and to correlate these subsets with clinical and laboratory data, which may help in clarifying the pathogenesis to develop novel diagnostic and prognostic biomarkers for COVID-19.</p><p><strong>Methods: </strong>Twenty-six reverse-transcription polymerase chain reaction (RT-PCR) confirmed COVID-19 patients were subjected to medical history-taking and a thorough clinical examination. Laboratory tests included complete blood count, D dimer, ferritin, and C-reactive protein (CRP). Chest CT was used to diagnose COVID-19 pneumonia. Lymphocyte subsets were compared with those in 20 healthy controls using flow cytometry.</p><p><strong>Results: </strong>Leucopenia, relative neutrophilia, lymphopenia, eosinopenia together with marked elevation in neutrophil/lymphocyte ratio were observed in our COVID-19 patients. A marked reduction was observed in T cells, including both CD4 and CD8 cells, natural killer (NK), and natural killer T cells (NKT). Double-positive T (DPT) cells, double-negative T (DNT) cells, and B cells were elevated in the patients relative to the other lymphocyte subsets.</p><p><strong>Conclusion: </strong>Immune-inflammatory parameters are of utmost importance in understanding the pathogenesis and in the provisional diagnosis of COVID-19. Yet, adequate care must be taken during their interpretation because of the vast discrepancies observed between studies even in the same locality. Further studies are needed to clarify the role of B cells, DPT, and DNT cells in the pathogenesis and control of COVID-19.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"16 2","pages":"758"},"PeriodicalIF":2.3,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/60/mrm-16-1-758.PMC8215531.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39157757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-25eCollection Date: 2021-01-15DOI: 10.4081/mrm.2021.759
Federico Raimondi, Luca Novelli, Gianmariano Marchesi, Fabrizio Fabretti, Lorenzo Grazioli, Ivano Riva, Chiara Allegri, Roberta Biza, Chiara Galimberti, Ferdinando Luca Lorini, Fabiano Di Marco
Background: In COVID-19, higher than expected level of intrapulmonary shunt has been described, in association with a discrepancy between the initial relatively preserved lung mechanics and the hypoxia severity. This study aim was to measure the shunt fraction and variations of PaO2/FiO2 ratio and oxygen alveolar-arterial gradient (A-a O2) at different FiO2.
Methods: Shunt was measured by a non-invasive system during spontaneous breathing in 12 patients hospitalized at COVID-19 Semi-Intensive Care Unit of Papa Giovanni XXIII Hospital, Bergamo, Italy, between October 22 and November 23, 2020.
Results: Nine patients were men, mean age (±SD) 62±15 years, mean BMI 27.5±4.8 Kg/m2. Systemic hypertension, diabetes type 2 and previous myocardial infarction were referred in 33%, 17%, and 7%, respectively. Mean PaO2/FiO2 ratio was 234±66 and 11 patients presented a bilateral chest X-ray involvement. Mean shunt was 21±6%. Mainly in patients with a more severe respiratory failure, we found a progressive decrease of PaO2/FiO2 ratio with higher FiO2. Considering (A-a O2), we found a uniform tendency to increase with FiO2 increasing. Even in this case, the more severe were the patients, the higher was the slope, suggesting FiO2 insensitiveness due to a shunt effect, as strengthened by our measurements.
Conclusion: Relying on a single evaluation of PaO2/FiO2 ratio, especially at high FiO2, could be misleading in COVID-19. We propose a two steps evaluation, the first at low SpO2 value (e.g., 92-94%) and the second one at high FiO2 (i.e., >0.7), allowing to characterize both the amendable (ventilation/perfusion mismatch), and the fixed (shunt) contribution quote of respiratory impairment, respectively.
背景:在COVID-19中,已经描述了高于预期水平的肺内分流,这与初始相对保存的肺力学与缺氧严重程度之间的差异有关。本研究旨在测定不同FiO2浓度下的分流率、PaO2/FiO2比值及肺泡-动脉氧梯度(a - O2)的变化。方法:于2020年10月22日至11月23日在意大利贝加莫Papa Giovanni XXIII医院COVID-19半重症监护病房住院的12例患者中,采用无创系统测量自主呼吸时的分流。结果:男性9例,平均年龄(±SD) 62±15岁,平均BMI 27.5±4.8 Kg/m2。全身性高血压、2型糖尿病和既往心肌梗死分别占33%、17%和7%。平均PaO2/FiO2比值为234±66,11例患者出现双侧胸片受累。平均分流率为21±6%。主要在较严重的呼吸衰竭患者中,我们发现PaO2/FiO2比率随着FiO2的升高而逐渐降低。考虑(a -a - O2),我们发现随着FiO2的增加有统一的增加趋势。即使在这种情况下,患者越严重,斜率也越高,这表明由于分流效应导致的FiO2不敏感,我们的测量结果加强了这一点。结论:单纯依靠PaO2/FiO2比值评估,特别是在高FiO2情况下,可能会误导COVID-19。我们提出了两步评估,第一步是低SpO2值(例如92-94%),第二步是高FiO2值(即>0.7),从而分别表征可修正(通气/灌注失配)和固定(分流)呼吸损伤的贡献引用。
{"title":"Worsening of gas exchange parameters at high FiO<sub>2</sub> in COVID-19: misleading or informative?","authors":"Federico Raimondi, Luca Novelli, Gianmariano Marchesi, Fabrizio Fabretti, Lorenzo Grazioli, Ivano Riva, Chiara Allegri, Roberta Biza, Chiara Galimberti, Ferdinando Luca Lorini, Fabiano Di Marco","doi":"10.4081/mrm.2021.759","DOIUrl":"https://doi.org/10.4081/mrm.2021.759","url":null,"abstract":"<p><strong>Background: </strong>In COVID-19, higher than expected level of intrapulmonary shunt has been described, in association with a discrepancy between the initial relatively preserved lung mechanics and the hypoxia severity. This study aim was to measure the shunt fraction and variations of PaO<sub>2</sub>/FiO<sub>2</sub> ratio and oxygen alveolar-arterial gradient (A-a O<sub>2</sub>) at different FiO<sub>2</sub>.</p><p><strong>Methods: </strong>Shunt was measured by a non-invasive system during spontaneous breathing in 12 patients hospitalized at COVID-19 Semi-Intensive Care Unit of Papa Giovanni XXIII Hospital, Bergamo, Italy, between October 22 and November 23, 2020.</p><p><strong>Results: </strong>Nine patients were men, mean age (±SD) 62±15 years, mean BMI 27.5±4.8 Kg/m<sup>2</sup>. Systemic hypertension, diabetes type 2 and previous myocardial infarction were referred in 33%, 17%, and 7%, respectively. Mean PaO<sub>2</sub>/FiO<sub>2</sub> ratio was 234±66 and 11 patients presented a bilateral chest X-ray involvement. Mean shunt was 21±6%. Mainly in patients with a more severe respiratory failure, we found a progressive decrease of PaO<sub>2</sub>/FiO<sub>2</sub> ratio with higher FiO<sub>2</sub>. Considering (A-a O<sub>2</sub>), we found a uniform tendency to increase with FiO<sub>2</sub> increasing. Even in this case, the more severe were the patients, the higher was the slope, suggesting FiO<sub>2</sub> insensitiveness due to a shunt effect, as strengthened by our measurements.</p><p><strong>Conclusion: </strong>Relying on a single evaluation of PaO<sub>2</sub>/FiO<sub>2</sub> ratio, especially at high FiO<sub>2</sub>, could be misleading in COVID-19. We propose a two steps evaluation, the first at low SpO<sub>2</sub> value (<i>e.g</i>., 92-94%) and the second one at high FiO<sub>2</sub> (<i>i.e</i>., >0.7), allowing to characterize both the amendable (ventilation/perfusion mismatch), and the fixed (shunt) contribution quote of respiratory impairment, respectively.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"16 1","pages":"759"},"PeriodicalIF":2.3,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/76/mrm-16-1-759.PMC8168493.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39090596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-17eCollection Date: 2021-01-15DOI: 10.4081/mrm.2021.737
Irene Coloretti, Stefano Busani, Emanuela Biagioni, Sophie Venturelli, Elena Munari, Marco Sita, Lorenzo DallAra, Martina Tosi, Enrico Clini, Roberto Tonelli, Riccardo Fantini, Cristina Mussini, Marianna Meschiari, Giovanni Guaraldi, Andrea Cossarizza, Gaetano Alfano, Massimo Girardis
Background: The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV-2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID-19 patients requiring mechanical ventilation and admitted to intensive care unit.
Methods: The association between therapy with tocilizumab or anakinra and in-hospital mortality was assessed in consecutive adult COVID-19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparing patients who received to those who did not receive tocilizumab or anakinra and by using different multivariable Cox models adjusted for variables related to poor outcome, for the propensity to be treated with tocilizumab or anakinra and after patient matching.
Results: Sixty-six patients who received immunotherapy (49 tocilizumab, 17 anakinra) and 28 patients who did not receive immunotherapy were included. The in-hospital crude mortality was 30,3% in treated patients and 50% in nontreated (OR 0.77, 95% CI 0.56-1.05, p=0.069). The adjusted Cox model showed an association between therapy with immunotherapy and in-hospital mortality (HR 0.40, 95% CI 0.19-0.83, p=0.015). This protective effect was further confirmed in the analysis adjusted for propensity score, in the propensity-matched cohort and in the cohort of patients with invasive mechanical ventilation within 2 hours after ICU admission.
Conclusions: Although important limitations, our study showed that cytokine-blocking agents seem to be safe and to improve survival in COVID-19 patients admitted to ICU with ARDS and the need for mechanical ventilation.
背景:已经提出使用细胞因子阻断剂来调节COVID-19患者的炎症反应。Tocilizumab和anakinra被纳入当地方案,作为SARS-CoV-2感染的急性呼吸窘迫综合征(ARDS)危重患者的可选治疗。本队列研究评估了细胞因子阻滞剂治疗对需要机械通气并入住重症监护病房的COVID-19患者住院死亡率的影响。方法:评估tocilizumab或anakinra治疗与院内死亡率之间的关系,这些患者连续入住ICU并伴有中度至重度ARDS。通过比较接受tocilizumab或anakinra治疗的患者与未接受tocilizumab或anakinra治疗的患者,并通过使用不同的多变量Cox模型来调整与不良结果相关的变量,以评估使用tocilizumab或anakinra治疗的倾向以及患者匹配后的相关性。结果:66例接受免疫治疗的患者(49例tocilizumab, 17例anakinra)和28例未接受免疫治疗的患者纳入研究。治疗组的住院粗死亡率为30.3%,未治疗组为50% (OR 0.77, 95% CI 0.56-1.05, p=0.069)。调整后的Cox模型显示免疫治疗与住院死亡率之间存在相关性(HR 0.40, 95% CI 0.19-0.83, p=0.015)。在倾向评分调整后的分析中,在倾向匹配队列中,在ICU入院后2小时内有创机械通气患者队列中,进一步证实了这种保护作用。结论:尽管存在重要的局限性,但我们的研究表明,细胞因子阻断剂似乎是安全的,并且可以提高ICU合并ARDS并需要机械通气的COVID-19患者的生存率。
{"title":"Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study.","authors":"Irene Coloretti, Stefano Busani, Emanuela Biagioni, Sophie Venturelli, Elena Munari, Marco Sita, Lorenzo DallAra, Martina Tosi, Enrico Clini, Roberto Tonelli, Riccardo Fantini, Cristina Mussini, Marianna Meschiari, Giovanni Guaraldi, Andrea Cossarizza, Gaetano Alfano, Massimo Girardis","doi":"10.4081/mrm.2021.737","DOIUrl":"https://doi.org/10.4081/mrm.2021.737","url":null,"abstract":"<p><strong>Background: </strong>The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV-2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID-19 patients requiring mechanical ventilation and admitted to intensive care unit.</p><p><strong>Methods: </strong>The association between therapy with tocilizumab or anakinra and in-hospital mortality was assessed in consecutive adult COVID-19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparing patients who received to those who did not receive tocilizumab or anakinra and by using different multivariable Cox models adjusted for variables related to poor outcome, for the propensity to be treated with tocilizumab or anakinra and after patient matching.</p><p><strong>Results: </strong>Sixty-six patients who received immunotherapy (49 tocilizumab, 17 anakinra) and 28 patients who did not receive immunotherapy were included. The in-hospital crude mortality was 30,3% in treated patients and 50% in nontreated (OR 0.77, 95% CI 0.56-1.05, p=0.069). The adjusted Cox model showed an association between therapy with immunotherapy and in-hospital mortality (HR 0.40, 95% CI 0.19-0.83, p=0.015). This protective effect was further confirmed in the analysis adjusted for propensity score, in the propensity-matched cohort and in the cohort of patients with invasive mechanical ventilation within 2 hours after ICU admission.</p><p><strong>Conclusions: </strong>Although important limitations, our study showed that cytokine-blocking agents seem to be safe and to improve survival in COVID-19 patients admitted to ICU with ARDS and the need for mechanical ventilation.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"16 1","pages":"737"},"PeriodicalIF":2.3,"publicationDate":"2021-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/30/mrm-16-1-737.PMC8139121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39022829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-22eCollection Date: 2021-01-15DOI: 10.4081/mrm.2021.750
Sherif A A Mohamed, Azza AbdelHafeez, Ehab Kamel, Alaa Rashad
Background: The National Comprehensive Cancer Network (NCCN) has adopted the distress thermometer (DT) as one of the best-known distress-screening instruments. We have adopted a modified version of the NCCN distress thermometer. We questioned if this modified DT (m-DT) could be utilized for measuring the prevalence of psychological distress among COVID-19 patients.
Methods: The prospective study included 2 phases; modification of the original DT and its associated problem list (PL), and evaluation of this m-DT in measuring the prevalence of psychological distress among COVID-19 patients. Egyptian adult subjects with suspected or confirmed cases of COVID-19 at 2 University Hospitals were enrolled. Binary logistic regression tests were carried out to explore the association between the m-DT cut-off scores of 4 and the clinical variables.
Results: One hundred sixty-nine (60.4%) patients experienced significant distress (m-DT cut off score ≥4). Logistic regression showed that occupation, presence of special habits, length of quarantine time, worry, cough, shortness of breath, and fever, were independent factors associated with significant distress in COVID-19 patients.
Conclusion: With the modified distress thermometer (m-DT), 60% of Egyptian COVID-19 patients experienced significant distress. This distress was significantly related to age, marital status, occupation, presence or absence of special habits, and length of the quarantine time. With m-DT, the current study had identified worry, being a health-care worker, shortness of breath, fever, length of quarantine time, presence of special habits, and cough as independent factors associated with significant distress in COVID-19 patients. Further studies are warranted.
{"title":"Utility of a modified distress thermometer in screening COVID-19 patients for psychological distress: a prospective Egyptian study.","authors":"Sherif A A Mohamed, Azza AbdelHafeez, Ehab Kamel, Alaa Rashad","doi":"10.4081/mrm.2021.750","DOIUrl":"10.4081/mrm.2021.750","url":null,"abstract":"<p><strong>Background: </strong>The National Comprehensive Cancer Network (NCCN) has adopted the distress thermometer (DT) as one of the best-known distress-screening instruments. We have adopted a modified version of the NCCN distress thermometer. We questioned if this modified DT (m-DT) could be utilized for measuring the prevalence of psychological distress among COVID-19 patients.</p><p><strong>Methods: </strong>The prospective study included 2 phases; modification of the original DT and its associated problem list (PL), and evaluation of this m-DT in measuring the prevalence of psychological distress among COVID-19 patients. Egyptian adult subjects with suspected or confirmed cases of COVID-19 at 2 University Hospitals were enrolled. Binary logistic regression tests were carried out to explore the association between the m-DT cut-off scores of 4 and the clinical variables.</p><p><strong>Results: </strong>One hundred sixty-nine (60.4%) patients experienced significant distress (m-DT cut off score ≥4). Logistic regression showed that occupation, presence of special habits, length of quarantine time, worry, cough, shortness of breath, and fever, were independent factors associated with significant distress in COVID-19 patients.</p><p><strong>Conclusion: </strong>With the modified distress thermometer (m-DT), 60% of Egyptian COVID-19 patients experienced significant distress. This distress was significantly related to age, marital status, occupation, presence or absence of special habits, and length of the quarantine time. With m-DT, the current study had identified worry, being a health-care worker, shortness of breath, fever, length of quarantine time, presence of special habits, and cough as independent factors associated with significant distress in COVID-19 patients. Further studies are warranted.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"16 1","pages":"750"},"PeriodicalIF":2.3,"publicationDate":"2021-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/20/ae/mrm-16-1-750.PMC8082533.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38928436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}